Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roman Hakl

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Frontiers in Immunology|March 17, 2022
Risk Factors for Severe COVID-19 and Hospital Admission in Patients With Inborn Errors of Immunity - Results From a Multicenter Nationwide StudyTomas Milota, Marta Sobotkova, Jitka Smetanova, et al.
Advances in Therapy|June 10, 2026
Long-Term Integrated Safety and Efficacy of Garadacimab for Hereditary Angioedema ProphylaxisTimothy J Craig, Mar Guilarte, Huamin Henry Li, et al.
Frontiers in Genetics|July 20, 2023
Myeloid lineage cells evince distinct steady-state level of certain gene groups in dependence on hereditary angioedema severityLucie Ballonová, Přemysl Souček, Peter Slanina, et al.
Journal of Clinical Immunology|August 24, 2023
Systematic Approach Revealed SERPING1 Splicing-Affecting Variants to be Highly Represented in the Czech National HAE CohortHana Grombirikova, Viktor Bily, Premysl Soucek, et al.
Frontiers in Immunology|October 1, 2025
First report from the Czech national registry of inborn errors of immunity (2012-2025)Zita Chovancova, Eva Hlavackova, Roman Hakl, et al.
Lancet (London, England)|February 11, 2023
An investigational oral plasma kallikrein inhibitor for on-demand treatment of hereditary angioedema: a two-part, randomised, double-blind, placebo-controlled, crossover phase 2 trialEmel Aygören-Pürsün, Andrea Zanichelli, Danny M Cohn, et al.
Frontiers in Allergy|July 13, 2026
The Chronic Angioedema Registry: what the first 2 years since the implementation of the global registry have taught usThomas Buttgereit, Mathias Sulk, Jonathan A Bernstein, et al.
The Journal of Allergy and Clinical Immunology|October 25, 2020
Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trialBruce Zuraw, William R Lumry, Douglas T Johnston, et al.
The Lancet. Haematology|March 22, 2026
Oral deucrictibant for on-demand treatment of hereditary angioedema attacks (RAPIDe-1): a randomised, double-blind, placebo-controlled, phase 2 trialMarcus Maurer, Marcin Stobiecki, Anna Valerieva, et al.
The World Allergy Organization Journal|June 19, 2026
Sebetralstat for on-demand treatment of hereditary angioedema: A pooled analysis of placebo-controlled clinical trialsEmel Aygören-Pürsün, Danny M Cohn, Nancy Agmon-Levin, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Frontiers in Immunology|March 17, 2022
Risk Factors for Severe COVID-19 and Hospital Admission in Patients With Inborn Errors of Immunity - Results From a Multicenter Nationwide StudyTomas Milota, Marta Sobotkova, Jitka Smetanova, et al.
Advances in Therapy|June 10, 2026
Long-Term Integrated Safety and Efficacy of Garadacimab for Hereditary Angioedema ProphylaxisTimothy J Craig, Mar Guilarte, Huamin Henry Li, et al.
Frontiers in Genetics|July 20, 2023
Myeloid lineage cells evince distinct steady-state level of certain gene groups in dependence on hereditary angioedema severityLucie Ballonová, Přemysl Souček, Peter Slanina, et al.
Journal of Clinical Immunology|August 24, 2023
Systematic Approach Revealed SERPING1 Splicing-Affecting Variants to be Highly Represented in the Czech National HAE CohortHana Grombirikova, Viktor Bily, Premysl Soucek, et al.
Frontiers in Immunology|October 1, 2025
First report from the Czech national registry of inborn errors of immunity (2012-2025)Zita Chovancova, Eva Hlavackova, Roman Hakl, et al.
Lancet (London, England)|February 11, 2023
An investigational oral plasma kallikrein inhibitor for on-demand treatment of hereditary angioedema: a two-part, randomised, double-blind, placebo-controlled, crossover phase 2 trialEmel Aygören-Pürsün, Andrea Zanichelli, Danny M Cohn, et al.
Frontiers in Allergy|July 13, 2026
The Chronic Angioedema Registry: what the first 2 years since the implementation of the global registry have taught usThomas Buttgereit, Mathias Sulk, Jonathan A Bernstein, et al.
The Journal of Allergy and Clinical Immunology|October 25, 2020
Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trialBruce Zuraw, William R Lumry, Douglas T Johnston, et al.
The Lancet. Haematology|March 22, 2026
Oral deucrictibant for on-demand treatment of hereditary angioedema attacks (RAPIDe-1): a randomised, double-blind, placebo-controlled, phase 2 trialMarcus Maurer, Marcin Stobiecki, Anna Valerieva, et al.
The World Allergy Organization Journal|June 19, 2026
Sebetralstat for on-demand treatment of hereditary angioedema: A pooled analysis of placebo-controlled clinical trialsEmel Aygören-Pürsün, Danny M Cohn, Nancy Agmon-Levin, et al.
Pageof 3